Corvus Pharma (CRVS) stock surges as the company plans a Phase 2 trial for its lead asset against eczema following ...

While early, the results indicate drugs known as ITK inhibitors have the potential to match or surpass the efficacy observed with the injectable biologic Dupixent.

Early eczema trial success and heavy trading are rapidly reshaping how investors view this drug developer, today, Jan. 20, ...

After eight weeks, 75% of participants treated with the Corvus pill, called soquelitinib, achieved at least a 75% improvement ...

Nemolizumab (Nemluvio) relieved itchiness within two days for three times as many patients as a placebo, researchers reported Tuesday in the Journal of the European Academy of Dermatology and ...

Corvus Pharma reports encouraging data for its eczema drug soquelitinib, showing strong skin improvement and no serious ...

Millions of Brits with eczema are almost twice as likely to suffer agonising eye and bowel conditions, research suggests.

Man scratch oneself, dry flaky skin on hand with psoriasis vulgaris, eczema and other skin conditions like fungus, plaque, rash and patches. A recently approved injectable eczema drug provides quick ...

About three times as many eczema patients on nemolizumab had itch relief within two days compared to placebo Twice as many eczema patients slept better within two days FRIDAY, Dec. 19, 2025 (HealthDay ...